142 related articles for article (PubMed ID: 24042106)
1. Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection in a tertiary care hospital in Serbia.
Djordjevic Z; Folic M; Ruzic Zecevic D; Ilic G; Jankovic S
J Infect Dev Ctries; 2013 Sep; 7(9):686-90. PubMed ID: 24042106
[No Abstract] [Full Text] [Related]
2. Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit.
Kohlenberg A; Weitzel-Kage D; van der Linden P; Sohr D; Vögeler S; Kola A; Halle E; Rüden H; Weist K
J Hosp Infect; 2010 Apr; 74(4):350-7. PubMed ID: 20170982
[TBL] [Abstract][Full Text] [Related]
3. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
Carmeli Y; Lidji SK; Shabtai E; Navon-Venezia S; Schwaber MJ
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):367-72. PubMed ID: 21683268
[TBL] [Abstract][Full Text] [Related]
4. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.
Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693
[TBL] [Abstract][Full Text] [Related]
5. Metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in Brazil.
Viana Vieira V; Lourenço da Fonseca E; Paulo Vincente AC
Clin Microbiol Infect; 2005 Nov; 11(11):937. PubMed ID: 16216114
[No Abstract] [Full Text] [Related]
6. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections.
Lin KY; Lauderdale TL; Wang JT; Chang SC
J Microbiol Immunol Infect; 2016 Feb; 49(1):52-9. PubMed ID: 24662016
[TBL] [Abstract][Full Text] [Related]
7. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
[TBL] [Abstract][Full Text] [Related]
8. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Shigemi A; Matsumoto K; Yaji K; Shimodozono Y; Takeda Y; Miyanohara H; Kawamura H; Orita M; Tokuda K; Nishi J; Yamada K
Int J Antimicrob Agents; 2009 Dec; 34(6):589-91. PubMed ID: 19748231
[TBL] [Abstract][Full Text] [Related]
9. Associations between carbapenem use, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii.
Apisarnthanarak A; Jitpokasem S; Mundy LM
Infect Control Hosp Epidemiol; 2013 Nov; 34(11):1235-7. PubMed ID: 24113616
[No Abstract] [Full Text] [Related]
10. Heteroresistance to carbapenems in invasive Pseudomonas aeruginosa infections.
He J; Jia X; Yang S; Xu X; Sun K; Li C; Yang T; Zhang L
Int J Antimicrob Agents; 2018 Mar; 51(3):413-421. PubMed ID: 29127047
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa.
Tsao LH; Hsin CY; Liu HY; Chuang HC; Chen LY; Lee YJ
J Microbiol Immunol Infect; 2018 Jun; 51(3):359-366. PubMed ID: 28988663
[TBL] [Abstract][Full Text] [Related]
12. [Risk factors for Pseudomonas aeruginosa infections, resistant to carbapenem].
Ghibu L; Miftode E; Teodor A; Bejan C; Dorobăţ CM
Rev Med Chir Soc Med Nat Iasi; 2010; 114(4):1012-6. PubMed ID: 21500452
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
Kunakonvichaya B; Thirapanmethee K; Khuntayaporn P; Montakantikul P; Chomnawang MT
Int J Antimicrob Agents; 2015 May; 45(5):556-7. PubMed ID: 25724628
[No Abstract] [Full Text] [Related]
14. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
Eagye KJ; Nicolau DP
J Antimicrob Chemother; 2011 Jun; 66(6):1392-5. PubMed ID: 21459897
[TBL] [Abstract][Full Text] [Related]
15. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
Peña C; Guzmán A; Suarez C; Dominguez MA; Tubau F; Pujol M; Gudiol F; Ariza J
Antimicrob Agents Chemother; 2007 Jun; 51(6):1967-71. PubMed ID: 17420207
[TBL] [Abstract][Full Text] [Related]
16. Selection of carbapenem-resistant Pseudomonas aeruginosa in a haematology unit?
Garvey MI; Bradley CW; Biggs MJ; Holden E; Gill MJ
J Hosp Infect; 2018 Mar; 98(3):238-240. PubMed ID: 29126992
[No Abstract] [Full Text] [Related]
17. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
[No Abstract] [Full Text] [Related]
18. Molecular characterization of carbapenem-resistant Pseudomonas aeruginosa strains isolated from patients with urinary tract infections in Southern Poland.
Pobiega M; Maciąg J; Chmielarczyk A; Romaniszyn D; Pomorska-Wesolowska M; Ziolkowski G; Heczko PB; Bulanda M; Wojkowska-Mach J
Diagn Microbiol Infect Dis; 2015 Nov; 83(3):295-7. PubMed ID: 26341705
[TBL] [Abstract][Full Text] [Related]
19. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-beta-lactamase.
Cornaglia G; Mazzariol A; Lauretti L; Rossolini GM; Fontana R
Clin Infect Dis; 2000 Nov; 31(5):1119-25. PubMed ID: 11073738
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa.
Tam VH; Chang KT; LaRocco MT; Schilling AN; McCauley SK; Poole K; Garey KW
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):309-14. PubMed ID: 17617302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
